Scarica l'app Stockscreener
0.7256
1.79%
-0.0132
Dopo l'orario di chiusura:
.71
-0.0156
-2.15%
Precedente Chiudi:
$0.7388
Aprire:
$0.75
Volume 24 ore:
231.14K
Relative Volume:
0.20
Capitalizzazione di mercato:
$55.92M
Reddito:
-
Utile/perdita netta:
$-20.31M
Rapporto P/E:
-2.7433
EPS:
-0.2645
Flusso di cassa netto:
$-21.07M
1 W Prestazione:
-5.42%
1M Prestazione:
-13.21%
6M Prestazione:
-23.61%
1 anno Prestazione:
-28.86%
Intervallo 1D:
$0.72
$0.75
Intervallo di 1 settimana:
$0.712
$0.7782
Portata 52W:
$0.67
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Nome
Oncolytics Biotech Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta ONCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.7256 | 55.92M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-06 | Iniziato | Maxim Group | Buy |
| 2021-02-17 | Iniziato | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Borsa (ONCY) Ultime notizie
Oncolytics Biotech Inc. (NASDAQ:ONCY) Sees Significant Increase in Short Interest - MarketBeat
Investors Eye Biotech Sector as Cancer Therapy Market Surges - KamloopsBCNow
Oncolytics Biotech Inc - MENAFN.COM
Oncolytics Biotech advances pancreatic, anal cancer trials - TipRanks
USA News Group: Investors Eye Biotech Sector as Cancer Therapy Market Surges - FinanzNachrichten.de
This AI Stock Is Up 50% in 2025. Is It Too Late to Buy? - The Globe and Mail
Canadian Tire Corporation announces sale of Helly Hansen to Kontoor Brands; simplifying CTC portfolio to focus on Canadian retail growth - The Globe and Mail
Oncolytics Biotech Advances Cancer Trials, Strengthening 2025 Pipeline - TipRanks
Can This Dual Cancer Trial Success Transform Oncolytics' Market Position? - StockTitan
Prediction: Zoom Will Struggle to Beat the Market. Here's Why - The Globe and Mail
Oncolytics Biotech advances in cancer immunotherapy trials By Investing.com - Investing.com Canada
Oncolytics Biotech advances in cancer immunotherapy trials - Investing.com
Clinical Trial Success: Oncolytics' Cancer Drug Shows Superior Results in Two Major Cancer Types - StockTitan
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins - Financial Content
Oncolytics Biotech Advances Cancer Treatment Pipeline with Key 2025 Developments - TipRanks
Clinical Breakthrough: Oncolytics' Cancer Drug Shows Remarkable Results in Three Major Cancer Types - StockTitan
Oncolytics Biotech Gets Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency - Marketscreener.com
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
Pan American Silver Stock Forecast: Q4 2024 Earnings Preview - The Globe and Mail
Oncolytics Biotech receives Nasdaq non-compliance notice - MSN
Oncolytics Biotech faces Nasdaq delisting over share price - MSN
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Let - GuruFocus.com
Oncolytics Biotech Receives Nasdaq Notification for Bid Price Deficiency - TipRanks
Nasdaq Issues Warning: Oncolytics Biotech Faces Critical 6-Month Deadline to Avoid Delisting - StockTitan
Oncolytics Biotech Announces Leadership Change Amid CEO’s Health Concerns - TipRanks
AMC Networks (AMCX) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Oncolytic Virus Therapy Market Growth, Innovations, Demand & - openPR
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM) - The Globe and Mail
Oncolytics Biotech Announces Leadership Change Amid CEO Departure - TipRanks
Oncolytics Biotech (TSE:ONC) Shares Up 2.9%Time to Buy? - MarketBeat
Oncolytics Biotech (TSE:ONC) Sets New 1-Year LowHere's Why - MarketBeat
What is HC Wainwright's Estimate for ONCY FY2024 Earnings? - MarketBeat
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence - Lelezard
Oncolytics Biotech's Co-Founder CEO Exits: Critical Leadership Change Amid Cancer Drug Development - StockTitan
ONCYOncolytics Biotech, Inc. Common Shares Latest Stock News & Market Updates - StockTitan
Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX - Simply Wall St
Pre-Op Immunotherapy May Help Treat Aggressive Breast Cancers - 69News WFMZ-TV
FY2029 Earnings Estimate for TSE:ONC Issued By HC Wainwright - MarketBeat
Equities Analysts Offer Predictions for ONCY FY2024 Earnings - Defense World
Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock? - MSN
H.C. Wainwright maintains $5 target on Oncolytics Biotech stock - MSN
Can you now get a good deal on Oncolytics Biotech, Inc’s shares? - US Post News
FY2029 Earnings Forecast for ONCY Issued By HC Wainwright - Defense World
FY2029 Earnings Forecast for TSE:ONC Issued By HC Wainwright - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
Financial Metrics Exploration: Understanding Oncolytics Biotech, Inc (ONCY) Through Ratios - The Dwinnex
Brokers Offer Predictions for ONCY FY2029 Earnings - MarketBeat
Oncolytics Biotech Inc Azioni (ONCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):